BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)
Source Business Wire Health: Pharmaceutical NewsRead More
STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the first patient dosed in Phase 1 clinical trial evaluating FT-7051 in metastatic castration-resistant prostate cancer.
Source Business Wire...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts for Priority Review Application for Opdivo as Adjuvant Therapy for Patients w/Resected Esophageal or Gastroesophageal Junction Cancer...
BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune...
NEW YORK--(BUSINESS WIRE)--Acquisition of Myst Therapeutics adds proprietary tumor infiltrating lymphocyte (“TIL”) technology and programs to Turnstone’s growing portfolio
Source Read More
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the first patient dosed in Phase 1 clinical trial evaluating FT-7051 in metastatic castration-resistant prostate cancer.
Source Read More
